Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

NCT00674648 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

BIOLOGICAL: CMV-Peptide-Specific T cells

Sponsor

Memorial Sloan Kettering Cancer Center